Patents, patients, and public policy: an incomplete intersection at 35 U.S.C. Section 287(c).
作者信息
Ho C M
机构信息
Loyola University of Chicago School of Law, USA.
出版信息
Univ Calif Davis Law Rev. 2000 Spring;33(3):601-75.
PMID:16389678
Abstract
摘要
相似文献
1
Patents, patients, and public policy: an incomplete intersection at 35 U.S.C. Section 287(c).
Univ Calif Davis Law Rev. 2000 Spring;33(3):601-75.
2
Patients v. patents?: policy implications of recent patent legislation.
St Johns Law Rev. 1997;71:329-401.
3
ACOG Committee Opinion. Number 364 May 2007. Patents, medicine, and the interests of patients.
Obstet Gynecol. 2007 May;109(5):1249-54. doi: 10.1097/01.AOG.0000263899.30167.eb.
4
Equivalents in biotechnology patents.
Nat Biotechnol. 2003 Mar;21(3):329-31. doi: 10.1038/nbt0303-329.
5
US courts narrow patent exemptions.
Nat Biotechnol. 2003 Aug;21(8):834. doi: 10.1038/nbt0803-834.
6
Patent law--balancing profit maximization and public access to technology.
Columbia Sci Technol Law Rev. 2003;4:E1.
7
The importance of getting inventorship right.
Nat Biotechnol. 2006 Feb;24(2):153-4. doi: 10.1038/nbt0206-153.
8
Is the viability of the Lilly doctrine on the decline?
Nat Biotechnol. 2003 Aug;21(8):943-4. doi: 10.1038/nbt0803-943.
9
Determining the meaning of claim terms.
Nat Biotechnol. 2006 Jan;24(1):41-3. doi: 10.1038/nbt0106-41.
10
The 'Lilly doctrine' is viable and critical.
Nat Biotechnol. 2003 Oct;21(10):1131-2. doi: 10.1038/nbt1003-1131b.
Zotero 插件